|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.2021 - 0.2021|
|52 Week Range||0.0110 - 0.3217|
|Beta (5Y Monthly)||0.29|
|PE Ratio (TTM)||9.62|
|Forward Dividend & Yield||0.01 (7.21%)|
|Ex-Dividend Date||Sep 30, 2022|
|1y Target Est||N/A|
NexgenRx's (CVE:NXG) stock is up by a considerable 30% over the past three months. Since the market usually pay for a...
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
NEXGENRX INC.("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2022, highlighted by continued revenue growth, positive EBIDTA and increased free cash flow. During Q3 2022, the Company showed revenue growth of 15.81% over the same period last year. Revenue for the third quarter was $3,317,358 and $9,401,460 year-to-date.